Zhang Yu, Zhu Xiaofei, Liu Ri, Wang Xianglian, Sun Gaofeng, Song Jiaqi, Lu Jianping, Zhang Huojun
Department of radiology, Changhai Hospital Affiliated to the Second Military Medical University, Changhai Road 168, Yangpu district, Shanghai, 200433, P.R. China.
Department of oncology radiation, Changhai Hospital Affiliated to the Second Military Medical University, Changhai Road 168, Yangpu district, Shanghai, 200433, P.R. China.
Transl Oncol. 2018 Apr;11(2):399-405. doi: 10.1016/j.tranon.2018.01.012. Epub 2018 Feb 20.
To identify whether the combination of pre-treatment radiological and clinical factors can predict the overall survival (OS) in patients with locally advanced pancreatic cancer (LAPC) treated with stereotactic body radiation and sequential S-1 (a prodrug of 5-FU combined with two modulators) therapy with improved accuracy compared with that of established clinical and radiologic risk models.
Patients admitted with LAPC underwent diffusion weighted imaging (DWI) scan at 3.0-T (b = 600 s/mm). The mean signal intensity (SI = 600) of region-of-interest (ROI) was measured. The Log-rank test was done for tumor location, biliary stent, S-1, and other treatments and the Cox regression analysis was done to identify independent prognostic factors for OS. Prediction error curves (PEC) were used to assess potential errors in prediction of survival. The accuracy of prediction was evaluated by Integrated Brier Score (IBS) and C index.
41 patients were included in this study. The median OS was 11.7 months (2.8-23.23 months). The 1-year OS was 46%. Multivariate analysis showed that pre-treatment SI = 600 value and administration of S-1 were independent predictors for OS. The performance of pre-treatment SI = 600 and S-1 treatment in combination was better than that of SI = 600 or S-1 treatment alone.
The combination of pre-treatment SI = 600 and S-1 treatment could predict the OS in patients with LAPC undergoing SBRT and sequential S-1 therapy with improved accuracy compared with that of established clinical and radiologic risk models.
确定与已建立的临床和放射学风险模型相比,治疗前的放射学和临床因素相结合是否能更准确地预测接受立体定向体部放疗和序贯S-1(一种5-氟尿嘧啶前药与两种调节剂的组合)治疗的局部晚期胰腺癌(LAPC)患者的总生存期(OS)。
收治的LAPC患者接受3.0-T的扩散加权成像(DWI)扫描(b = 600 s/mm)。测量感兴趣区(ROI)的平均信号强度(SI = 600)。对肿瘤位置、胆道支架、S-1和其他治疗进行对数秩检验,并进行Cox回归分析以确定OS的独立预后因素。使用预测误差曲线(PEC)评估生存预测中的潜在误差。通过综合Brier评分(IBS)和C指数评估预测准确性。
本研究纳入41例患者。中位OS为11.7个月(2.8 - 23.23个月)。1年OS率为46%。多变量分析显示,治疗前SI = 600值和S-1的使用是OS的独立预测因素。治疗前SI = 600与S-1治疗联合使用的性能优于单独使用SI = 600或S-1治疗。
与已建立的临床和放射学风险模型相比,治疗前SI = 600与S-1治疗相结合能更准确地预测接受立体定向体部放疗和序贯S-1治疗的LAPC患者的OS。